Ribociclib
Novartis
['natalee', 'kisqali', 'breast', 'point data', 'novartis', '$nvs']
$nvs(97.11) up 1 says kisqali reduced risk of breast cancer recurrence by 25% in
study - novartis presented "positive primary endpoint data" from the pivotal
phase 3 natalee trial at the 2023 american society of clinical oncology, or
asco,
Very varied...trading stocks, futures, options, fishing, hunting, cooking, wanting to make a difference. All posts are for entertainment purposes only.